Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
30 June, 2015 19:58 IST
Protonix settlement a blow to Sun Pharma's near-term acquisition plans
Source: IRIS | 13 Jun, 2013, 10.27AM
Comments  |  Post Comment

Sun Pharmaceutical Industries said Wednesday the company settled litigation pending in the United States District Court, District of New Jersey (Court) regarding Sun Pharma (Q,N,C,F)* subsidiary's generic pantoprazole. Sun Pharma will pay USD 550 million to Pfizer Inc and Atlanta Pharma AG as a part of this settlement. It will continue to sell its generic pantoprazole in the U.S.

In 2005, Wyeth and Altana had filed a patent infringement suit against Sun after it filed its ANDA for Pantoprazole. Sun launched its generic Pantoprazole in the US on Jan. 30, 2008 at risk. In April 2010, a jury had determined that Altana's patent was valid. Wyeth had sought USD 960 million for the so called infringement. The Protonix patent had expired in January 2011. On Jun. 3, 2013, the court began a jury trial to assess the amount of past damages that Sun Pharma owed for infringing Altana's now expired patent. The settlement has effectively neutralised the ongoing litigation. Sun has already provided for USD 107 million in Q2FY13.

Commenting on the development, ICICIdirect said, ''As the settlement amount is unprecedented, the stock is likely to witness knee-jerk reaction in the near term. However, the event was not entirely unexpected. Sun will have to shell out Rs 30 billion out of its cash pile of Rs 54 billion as on Mar. 31, 2013, thus effectively putting its immediate acquisition plans in jeopardy. We have cut our FY14E and FY15E EPS estimates by Rs 27 and Rs 5, respectively, owing to a dent in other income (treasury income). Our revised target price now stands at Rs  976 i.e. 23x FY15E (revised) EPS of Rs 42.4. We maintain Hold. Any swift correction can be used as an opportunity to re-enter the stock as all other strongholds remain intact.''

It has maintained 'Hold' on Sun Pharmaceuticals with target price of Rs 976 as against current market price (CMP) of Rs 981 in its report.

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
SBI and MakeMyTrip announces strategic alliance to unlock synergy between banking and tourism - 30-Jun-2015 17:44
Blue Star Infotech wins a USD 15 mn deal - 30-Jun-2015 17:33
Hero Motocorp launches 'Xtreme Sports' - 30-Jun-2015 17:12
Aurionpro appoints Deependra Chumble as chief people officer - 30-Jun-2015 16:52
UPL acquires 40% stake in Sinagro Group - 30-Jun-2015 16:30
Ashok Leyland awarded contract to supply of 633 vehicles - 30-Jun-2015 15:32
Prakash Industries deposits Rs 148.5 mn with Coal Controller - 30-Jun-2015 15:28
Prakash Industries deposits Rs 148.5 mn with Coal Controller - 30-Jun-2015 15:28
KPTL bags new orders worth Rs 10.35 bn - 30-Jun-2015 15:23
Nestle India shares surge after Bombay HC allows export of Maggi noodles - 30-Jun-2015 14:22
Bombay HC allows Nestle to export Maggi Noodles - 30-Jun-2015 14:17
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer